Group 1 - The company expects to achieve an unaudited consolidated profit attributable to shareholders of approximately $23.5 million for the nine months ending September 30, 2025, compared to $4.3 million for the same period ending September 30, 2024, indicating significant profit growth driven by a substantial increase in revenue [1] - The profit growth is attributed to the successful implementation of key strategies focused on developing large customer sales [1] - However, due to a slowdown in China's livestock industry, the demand for the company's animal health pharmaceutical products is expected to decrease starting from the third quarter of 2025 [1] Group 2 - The company anticipates that its unaudited quarterly profit attributable to shareholders for the three months ending September 30, 2025, will decline to approximately $6.5 million, down from $9.3 million for the three months ending June 30, 2025 [1]
正大企业国际(03839)发盈喜，预期前三季度股东应占综合溢利约2350万美元 同比增加